Health Care Supplies

20/20 Biolabs

20/20 Biolabs released FY2025 Q4 earnings on March 31 (EST), actual revenue USD 538.27K, actual EPS USD -0.2556

20/20 Biolabs released FY2024 Q4 earnings on March 31 (EST), actual revenue USD 536.08K, actual EPS USD -0.2589

20/20 Biolabs released FY2025 Annual Earnings on March 31 (EST), actual revenue USD 2.045 M, actual EPS USD -0.7583

20/20 Biolabs launches ONETEST based on IBM's AI

20/20 Biolabs released FY2024 Q3 earnings on December 12 (EST), actual revenue USD 361.01K, actual EPS USD -0.3906

20/20 Biolabs released FY2024 9 Months earnings on December 12 (EST), actual revenue USD 1.216 M, actual EPS USD -0.8991

20/20 Biolabs released FY2025 Q3 earnings on December 12 (EST), actual revenue USD 417.98K, actual EPS USD -0.1683

20/20 Biolabs released FY2025 9 Months earnings on December 12 (EST), actual revenue USD 1.507 M, actual EPS USD -0.5012

20/20 Biolabs released FY2025 Q1 earnings on September 22 (EST), actual revenue USD 544.44K, actual EPS USD -0.1664

AIDX.US released FY2024 Q1 earnings on September 22, 2025 (BJT) with actual revenue of USD 427.63K and EPS of USD -0.2542

20/20 Biolabs released FY2024 Semi-Annual earnings on September 22, 2025 (EST), with actual revenue of USD 855.25 K and EPS of USD -0.5084

AIDX.US released FY2024 Q2 earnings on September 22, 2025 (BJT), actual revenue USD 427.63K, actual EPS USD -0.2542

20/20 Biolabs released FY2025 Q2 earnings on September 22 (EST), actual revenue USD 544.44K, actual EPS USD -0.1664

20/20 Biolabs released FY2025 Semi-Annual Earnings on September 22 (EST), actual revenue USD 1.089 M, actual EPS USD -0.3328

20/20 Biolabs released FY2023 Q4 earnings on April 30 (EST), actual revenue USD 334.49K, actual EPS USD -0.2807

20/20 Biolabs released FY2023 Annual Earnings on April 30, 2025 (EST), with actual revenue of USD 1.424 M and EPS of USD -1.3402

20/20 Biolabs released FY2024 earnings on April 30 (EST), actual revenue USD 1.752 M, actual EPS USD -1.0679

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

AIDX

20/20 Biolabs, Inc. reported a revenue decline to $353.38K in Q1 2026, with a net loss of $2.12M and diluted EPS of ($0.28), compared to ($0.16) a year ago. The drop in revenue was attributed to lower OneTest and BioCheck sales, and a major OneTest renewal was delayed. The company launched OneTest for Longevity and increased R&D spending to support its product pipeline.

TradingView

20/20 Biolabs, Inc. 1Q 2026: Revenue $353.38K, EPS ($0.28) — 10-Q Summary

Earnings Watch

20/20 Biolabs | 10-Q: FY2026 Q1 Revenue: USD 353.38 K

20/20 BioLabs reported its Q1 2026 financials, highlighting operational advancements. The country's economy grew by 3.5%, exceeding the 2.8% forecast, driven by a 6.1% rise in consumer spending and a 4.2% increase in exports. The unemployment rate fell to 4.2%, the lowest in a decade, leading analysts to express optimism for the upcoming quarter.

Unusual Whales

20/20 BioLabs reveals Q1 2026 financials and recent operational advancements.

University of South Carolina has exclusively licensed the PSA Velocity Algorithm to 20/20 BioLabs. In related news, the country is facing a surge in coronavirus cases, surpassing 500,000, with over 10,000 deaths. The government has enacted stricter measures, including mandatory masks and limited public capacity, while vaccination efforts have seen over 1 million doses administered. Health officials continue to urge compliance with guidelines to mitigate the virus's spread, and the situation is under close observation for further updates.

University of South Carolina licenses PSA Velocity Algorithm exclusively to 20/20 BioLabs in a new deal.

HEALWELL AI Inc. will hold a conference call on May 8, 2026, at 8:30 am ET to discuss its Fiscal First Quarter 2026 financial results, which will be released after market close on May 7, 2026. The call will be hosted by CEO James Lee, President Dr. Alexander Dobranowski, and CFO Anthony Lam. HEALWELL AI focuses on preventative healthcare through advanced clinical decision support systems. The company is publicly traded on the TSX under "AIDX" and OTC under "HWAIF."

StockTitan

HEALWELL AI Announces Conference Call for First Quarter 2026 Financial Results on May 8, 2026 | HWAIF Stock News

20/20 Biolabs reported fiscal-year revenue of $2.045 million, a 16.7% increase from the previous year, but recorded a net loss of $(3.739) million. Gross profit improved to $0.605 million with a 29.56% margin. The growth was driven by higher OneTest sales and a shift to a premium test mix. The company launched a new product, OneTest for Longevity, and began multi-cancer screenings for veterans, indicating market expansion. Cost efficiency initiatives led to improved gross margins and reduced operating expenses.

20/20 Biolabs 10-K: Revenues $2.05M, Net Loss $(3.74) M

20/20 BioLabs reported a 17% revenue increase to $2.0 million for FY 2025, with gross profit rising 68% and gross margin expanding to 29.6%. The company aims for significant growth in 2026, driven by a state-funded cancer screening program and recent Nasdaq listing under ticker AIDX. Operating expenses decreased by 35%, and net loss improved by 33%. The launch of OneTest™ for Longevity and a partnership with ROKIT Healthcare are key initiatives. Management expresses confidence in future growth, supported by public sector funding and innovative cancer detection tools.

20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress | AIDX Stock News

20/20 BioLabs, Inc. has announced that 18 Maryland fire departments will receive over $520,000 from the Maryland Department of Health for the OneTest™ multi-cancer early detection blood test. This funding, part of a state initiative, aims to screen over 1,400 firefighters, reflecting a 225% increase from last year. The initiative highlights the growing support for innovative cancer detection tools, especially for firefighters at higher risk for cancer. The company plans to seek Medicare coverage for its tests, which utilize AI and aim for better detection rates and cost-effectiveness.

Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test | AIDX Stock News

20/20 BioLabs, Inc. has secured an exclusive U.S. license to integrate ROKIT Healthcare's chronic kidney disease (CKD) prediction algorithm into its OneTest for Longevity platform. This partnership aims to enhance predictive insights for chronic disease prevention, offering personalized risk assessments for CKD, which affects over 35 million Americans. The collaboration also includes financial arrangements for sales and marketing expenses. AIDX, which recently began trading on Nasdaq, closed at $1.64, down 17.59%.

nasdaq

20/20 BioLabs Secure U.S. License For Advanced CKD Prediction Technology

20/20 Biolabs(AIDX.US)